

PEAKEDLABS

The Complete Guide to Peptide Therapy

An evidence-aware buyer's guide to GLP-1 medicines, hormone-related treatments, and experimental peptides.

Make a better treatment decision—
not just a better purchase.

SEPTEMBER 5, 2026 RESEARCH EDITION

Human evidence · Provider verification · Annual cost worksheets

Contents

Before you begin 2

1. Start with a decision, not a molecule 4

2. Read the evidence without becoming a scientist 7

3. The US regulatory map: five words that are not synonyms 10

4. GLP-1 medicines: compare treatments, not headlines 14

5. Growth-hormone claims, tesamorelin, and the TRT boundary 19

6. Injury, recovery, and “regeneration” peptides 23

7. Sexual health, sleep, cognition, skin, and longevity 26

8. Baseline assessment and monitoring that answer real questions 30

9. Prescription literacy without a do-it-yourself protocol 34

10. Adverse events: know the next action before you need it 37

11. Verify the provider, pharmacy, and product 40

12. Calculate the real annual cost 45

13. Turn the research into a useful clinician conversation 50

Workbook: eight pages to use, not just read 53

Glossary 61

Research methods, limitations, and linked bibliography 64

Annual line item	ClearPath, hypothetical	ReadyCare, hypothetical
Initial evaluation	\$125	\$0
Membership	$\$95 \times 12 = \$1,140$	$\$145 \times 12 = \$1,740$
Medication	$\$320 \times 12 = \$3,840$	$\$285 \times 3 + \$385 \times 9 = \$4,320$
Agreed laboratory costs	$\$180 \times 2 = \360	$\$240 + \$120 = \$360$
Additional billed follow-ups	Included	$\$65 \times 2 = \130
Shipping	Included	$\$15 \times 12 = \180
Required supplies	Included	Included
Total year-one cost	\$5,465	\$6,730
Average per calendar month	\$455.42	\$560.83

ReadyCare's opening medication quote is lower: \$285 versus \$320. Its first-month cash requirement is also lower under these assumptions: \$685 versus \$720, including each initial evaluation, first membership payment, first medication payment, baseline laboratory charge, and shipping. Yet its annual cost is **\$1,265 higher**.

The difference comes from the end of the promotional medication price, higher membership charges, shipping, and additional billed visits. None of those charges is necessarily improper. The problem would be presenting the introductory number as the full ongoing cost.

The conclusion is not "always choose ClearPath." If ReadyCare provides a clinically important service that ClearPath lacks, the difference may be worth discussing. The point is that you now know the amount you are comparing rather than mistaking a promotional medication price for an annual care budget.

What would change that conclusion?

Suppose the patient requires an additional service not included in ClearPath's plan. Add its actual quoted cost to ClearPath rather than assuming it is free. Suppose ReadyCare's medication price remains promotional longer than expected. Update the exact months, rather than applying a vague discount to the entire year.

Also check whether the two "same drug" offers really involve the same approved product and presentation. If one quietly substitutes a compounded preparation, the comparison is no longer merely financial. Return to the product and regulatory gates before comparing totals.

A spreadsheet cannot fix a mismatched comparison. First compare appropriate options; then compare the money.